“Patient Assessment of Foam Attributes from the Tazarotene Foam, 0.1%, Phase III Trials and Potential Impact on Patient Compliance”. SKIN The Journal of Cutaneous Medicine 2 (December 17, 2018): S57. Accessed October 13, 2025. https://skin.dermsquared.com/skin/article/view/455.